JD Esq - Aridis Pharmaceuticals Acting Counsel
| ARDSDelisted Stock | USD 0.27 0.02 8.00% |
Insider
JD Esq is Acting Counsel of Aridis Pharmaceuticals
| Age | 60 |
| Phone | 408 385 1742 |
| Web | https://www.aridispharma.com |
Aridis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.0753) % which means that it has lost $1.0753 on every $100 spent on assets. This is way below average. Aridis Pharmaceuticals' management efficiency ratios could be used to measure how well Aridis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Aridis Pharmaceuticals currently holds 6.13 M in liabilities. Aridis Pharmaceuticals has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aridis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aridis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aridis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aridis to invest in growth at high rates of return. When we think about Aridis Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Stefanie Johns | Hoth Therapeutics | 39 | |
| Miles Nunn | Akari Therapeutics PLC | 55 | |
| Anna Moore | Transcode Therapeutics | 62 | |
| Torsten Hombeck | Akari Therapeutics PLC | 54 | |
| James Rolke | Revelation Biosciences | 55 | |
| Amro Albanna | Aditxt Inc | 54 | |
| TsungShann Jiang | ABVC Biopharma | 70 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Ray MD | Akari Therapeutics PLC | 79 | |
| Xiaoqin MD | Avenue Therapeutics | 49 | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Gerald Proehl | Dermata Therapeutics | 65 | |
| Marc Cantillon | Reviva Pharmaceuticals Holdings | 66 | |
| CPA CPA | Aditxt Inc | 56 | |
| PharmD BCPS | Neurobo Pharmaceuticals | N/A | |
| Matthew Shatzkes | Aditxt Inc | N/A | |
| James Foster | Virax Biolabs Group | 39 | |
| Victor MD | Kodiak Sciences | 51 | |
| David Hale | Dermata Therapeutics | 75 | |
| Jane Springer | Hoth Therapeutics | 39 | |
Management Performance
| Return On Asset | -1.08 |
Aridis Pharmaceuticals Leadership Team
Elected by the shareholders, the Aridis Pharmaceuticals' board of directors comprises two types of representatives: Aridis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aridis. The board's role is to monitor Aridis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Aridis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aridis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Aridis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Aridis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.08 | ||||
| Operating Margin | (9.58) % | ||||
| Current Valuation | 12.11 M | ||||
| Shares Outstanding | 36.21 M | ||||
| Shares Owned By Insiders | 31.53 % | ||||
| Shares Owned By Institutions | 11.60 % | ||||
| Number Of Shares Shorted | 2 M | ||||
| Price To Earning | (1.41) X | ||||
| Price To Book | 5.40 X | ||||
| Price To Sales | 7.33 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |